Regulation of transcription by the Epstein-Barr virus nuclear antigen EBNA 2

Biochemical Society Transactions

Volumn 36, Issue 4, 2008, Pages 625-628

  Palermo, Richard D ^a   Webb, Helen M ^a   Gunnell, Andrea ^a   West, Michelle J ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

C terminal domain phosphorylation (CTD phosphorylation); Cyclin dependent kinase 9 (CDK9); Elongation; Epstein Barr nuclear antigen 2 (EBNA 2); Epstein Barr virus (EBV); Transcription

Indexed keywords

ANDROGEN RECEPTOR; ANTIVIRUS AGENT; AROMATIC HYDROCARBON RECEPTOR; CD20 ANTIBODY; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN A; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 8; CYCLIN DEPENDENT KINASE 9; CYCLIN T1; E1A PROTEIN; EPSTEIN BARR VIRUS ANTIGEN 2; FLAVOPIRIDOL; HISTONE ACETYLTRANSFERASE PCAF; HISTONE H3; HISTONE H4; IMMUNOGLOBULIN J RECOMBINATION SIGNAL SEQUENCE BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; NUCLEAR RECEPTOR NUR77; POSITIVE TRANSCRIPTION ELONGATION FACTOR B; PROTEIN P300; PROTEIN P62; PROTEIN VP16; RNA POLYMERASE; TATA BINDING PROTEIN ASSOCIATED FACTOR; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR IIB; TRANSCRIPTION FACTOR PU 1; UNINDEXED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; B LYMPHOCYTE; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INFECTIOUS MONONUCLEOSIS; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; STEM CELL TRANSPLANTATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRAL GENETICS; VIRUS CELL INTERACTION; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS TRANSCRIPTION;

ANTIVIRAL AGENTS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION; HERPESVIRUS 4, HUMAN; HUMANS; PHOSPHORYLATION; TRANSCRIPTION, GENETIC; VIRAL PROTEINS;

HUMAN HERPESVIRUS 4;

EID: 49349115992     PISSN: 03005127     EISSN: None     Source Type: Journal    
DOI: 10.1042/BST0360625     Document Type: Article

References (49)

1. Lee, M.A., Diamond, M.E. and Yates, J.L. (1999) Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus, J. Virol. 73, 2974-2982
2. Skare, J., Farley, J, Strominger, J.L., Fresen, K.O., Cho, M.S. and zur Hausen, H. (1985) Transformation by Epstein-Barr virus requires DNA sequences in the region of BarnHI fragments Y and H. J. Virol. 55, 286-297
3. Cohen, J.I., Wang, F., Mannick, J. and Kieff, E. (1989) Elpstein-Barr, virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl. Acad. Sci. U.S.A. 86, 9558-9562
4. Tomkinson, B., Robertson, E. and Kieff, E. (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67, 2014-2025
5. Waltzer, L., Logeat, F., Brou, C., Israel, A., Sergeant, A. and Manet, E. (1994) The human Jκ recombination signal sequence-binding protein (RBP-Jκ) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J. 13, 5633-5638
6. Grossman, S.R., Johannsen, E., Tong, X., Yalamanchili, R. and Kieff, E. (1994) The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the Jκ recombination signal binding protein. Proc. Natl. Acad. Sci. U.S.A. 91, 7568-7572
7. Zimber-Strobl, U., Strobl, L.J., Meitinger, C., Hinrichs, R., Sakai, T., Furukawa, T., Honjo, T. and Bornkamm, G.W. (1994) Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-Jκ, the homologue of Drosophilo Suppressor of Hairless. EMBO J. 13, 4973-4982
8. Henkel, T., Ling, P.D., Hayward, S.D. and Peterson, M.G. (1994) Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein Jκ. Science 265, 92-95
9. Johannsen, E., Koh, E., Mosialos, G., Tong, X., Kieff, E. and Grossman, S.R. (1995) Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by Jκ and PU. 1. J. Virol. 69, 253-262
10. Wang, F., Tsang, S.F., Kurilla, M.G., Cohen, J.I. and Kieff, E. (1990) Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J. Virol. 64, 3407-3416
11. Abbot, S.D., Rowe, M., Cadwallader, K., Ricksten, A., Gordon J, Wang, F., Rymo, L. and Rickinson, A.B. (1990) Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J. Virol. 64, 2126-2134
12. Cohen, J.I. and Kieff, E. (1991) An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J. Virol. 65, 5880-5985
13. Cohen, J.I. (1992) A region of herpes simplex virus VP16 can substitute for a transforming domain of Epstein-Barr virus nuclear protein 2. Proc. Natl. Acad. Sci. U.S.A. 89, 8030-8034
14. Tong, X., Drapkin, R., Yalamanchili, R., Mosialos, G. and Kieff, E. (1995) The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol. Cell. Biol. 15, 4735-4744
15. Tong, X., Drapkin, R., Reinberg, D. and Kieff, E. (1995) The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. Proc. Natl. Acad. Sci. U.S.A. 92, 3259-3263
16. Tong, X., Wang, F., Thut, C.J. and Kieff, E. (1995) The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J. Virol. 69, 585-588
17. Wang, L., Grossman, S.R. and Kieff, E. (2000) Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter. Proc. Natl. Acad. Sci. U.S.A. 97, 430-435
18. Wu, D.Y., Kalpana, G.V., Goff, S.P. and Schubach, W,H. (1996) Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J. Virol. 70, 6020-6028
19. Alazafd, N., Gruffat, H., Hiriart, E., Sergeant, A. and Manet, E. (2003) Differential hyperacetylation of histones H3 and H4 upon promoter-specific recruitment of EBNA2 in Epstein-Barr virus chromatin. J. Virol. 77, 8166-8172
20. Yue, W., Shackelford, J. and Pagano, J.S. (2006) cdc2/cyclin B1-dependent phosphorylation of EBNA2 at Ser243 regulates its function in mitosis. J. Virol. 80, 2045-2050
21. Yue, W., Davenport, M.G., Shackelford, J. and Pagano, J.S. (2004) Mitosis-specific hyperphosphorylation of Epstein-Barr virus nuclear antigen 2 suppresses its function. J. Virol. 78, 3542-3552
22. Palancade, B. and Bensaude, O. (2003) Investigating RNA polymerase II carboxyl-terminal domain (CTD) phosphorylation. Eur. J. Biochem. 270, 3859-3870
23. Lee, D.K., Duan, H.O. and Chang, C. (2001) Androgen receptor interacts with the positive elongation factor P-TEFb and enhances the efficiency of transcriptional elongation. J. Biol. Chem. 276, 9978-9984
24. Tian, Y., Ke, S., Chen, M. and Sheng, T. (2003) Interactions between the aryl hydrocarbon receptor and P-TEFb: sequential recruitment of transcription factors and differential phosphorylation of C-terminal domain of RNA polymerase II at cyp1a1 promoter. J. Biol. Chem. 278, 44041-44048
25. Eberhardy, S.R. and Farnham, P.J. (2002) Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter. J. Biol. Chem. 277, 40156-40162
26. Gold, M.O., Tassan, J.P., Nigg, E.A., Rice, A.P. and Herrmann, C.H. (1996) Viral transactivators E1A and VP16 interact with a large complex that is associated with CTD kinase activity and contains CDK8. Nucleic Acids Res. 24, 3771-3777
27. Isel, C. and Karn, J. (1999) Direct evidence that HIV-1 Tat stimulates RNA polymerase II carboxyl-terminal domain hyperphosphorylation during transcriptional elongation. J. Mol. Biol. 290, 929-941
28. 5-phosphorylation of RNA Pol II. EMBO J. 22, 5125-5136
29. Bark-Jones, S.J., Webb, H.M. and West, MJ. (2006) EBV EBNA 2 stimulates CDK9-dependent transcription and RNA polymefase II phosphorylation on serine 5. Oncogene 25, 1775-1785
30. Kim, Y.K., Bourgeois, C.F., Isel, C., Churcher, M.J. and Karn, J. (2002) Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol. Cell. Biol. 22, 4622-4637
31. Zhou, M., Halanski, M.A., Radonovich, M.F., Kashanchi, F., Peng, J., Price, D.H. and Brady, J.N. (2000) Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription. Mol. Cell. Biol. 20, 5077-5086
32. Ramanathan, Y., Rajpara, S.M., Reza, S.M., Lees, E., Shuman, S., Mathews, M.B. and Pe'ery, T. (2001) Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences. J. Biol. Chem. 276, 10913-10920
33. Alfieri, C., Birkenbach, M. and Kieff, E. (1991) Early events in Epstein-Barr virus infection of human B lymphocytes. Virology 181, 595-608
34. Allday, M.J., Crawford, D.H. and Griffin, B.E. (1989) Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. J. Gen. Virol. 70, 1755-1764
35. Bell, A., Skinner, J., Kirby, H. and Rickinson, A. (1998) Characterisation of regulatory sequences at the Epstein-Barr virus BamHI W promoter. Virology 252, 149-161
36. Woisetschlaeger, M., Jin, X.W., Yandava, C.N., Furmanski, L.A., Strominger, J.L. and Speck, S.H. (1991) Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection. Proc. Natl. Acad. Sci. U.S.A. 88, 3942-3946
37. Sedlacek, H.H. (2001) Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 38, 139-170
38. Chao, S.H. and Price, D.H. (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem. 276, 31793-31799
39. Ma, Y., Cress, W.D. and Haura, E.B. (2003) Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol. Cancer Ther. 2, 73-81
40. Patel, V., Senderowicz, A.M., Pinto, Jr, D., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J.F., Sausville, E.A. and Gutkind, J.S. (1998) Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. 102, 1674-1681
41. Chao, S.H., Fujinaga, K., Marion, J.E., Taube, R., Sausville, E.A., Senderowicz, A.M., Peterlin, B.M. and Price, D.H. (2000) Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J. Biol. Chem. 275, 28345-28348
42. Gold, M.O., Yang, X., Herrmann, C.H. and Rice, A.P. (1998) PITALRE, the catalytic subunit of TAK, is required for human immunodeficiency virus Tat transactivation in vivo. J. Virol. 72, 4448-4453
43. Zhu, Y., Pe'ery, T., Peng, J., Ramanathan, Y., Marshall, N., Marshall, T., Amendt, B., Mathews, M.B. and Price, D.H. (1997) Transcription elongation factor P-TEFb is required for HIV-1 Tat transactivation in vitro. Genes Dev. 11, 2622-2632
44. Nelson, P.J., D'Agati, V.D., Gries, J.M., Suarez, J.R. and Gelman, I.H. (2003) Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. J. Antimicrob. Chemother. 51, 921-929
45. Svoboda, J., Kotloff, R. and Tsai, D.E. (2006) Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab. Transpl. Int. 19, 259-269
46. 1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 14, 88-96
47. Lee, J.M., Lee, K.H., Farrell, C.J., Ling, P.D., Kempkes, B., Park, J.H. and Hayward, S.D. (2004) EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J. Virol. 78, 12694-12697
48. Lee, J.M., Lee, K.H., Weidner, M., Osborne, B.A. and Hayward, S.D. (2002) Epstein-Barr virus EBNA2 blocks Nur77-mediated apoptosis. Proc. Natl. Acad. Sci. U.S.A. 99, 11878-11883
49. Farrell, C.J., Lee, J.M., Shin, E.C., Cebrat, M., Cole, P.A. and Hayward, S.D. (2004) Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc. Natl. Acad. Sci. U.S.A. 101, 4625-4630